Advanced Life Sciences Announces Collaboration With UK Ministry of Defence on ALS-886
CHICAGO, July 17, 2008 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that the United Kingdom's Defence Science and Technology Laboratory ("Dstl") will evaluate the developmental compound ALS-886 as a treatment for chemically induced lung injury. ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in reducing and preventing tissue damage in the lungs. Dstl has experience modeling lung injury and will conduct animal efficacy studies to measure the ability of ALS-886 to improve the clinical outcome following lung injury that results from the inhalation of chemicals that damage the lung surface.
"While we remain focused on our cethromycin partnering and NDA submission activities, we have continued our efforts on the biodefense front. In this regard, we have been pleased to identify additional opportunities to advance our pipeline programs along the way. Thus, we are excited to announce that Dstl has selected ALS-886 for evaluation as a novel therapy with potential to reduce the effects that result from damage to the lung surface," said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. "Dstl is internationally recognized for its ability to evaluate new therapeutic countermeasures that combat chemical and biological warfare agents, and we are very excited to partner with them to develop ALS-886 for potential procurement as a medical countermeasure."
ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in both scavenging existing free radicals and sequestering free iron. Animal toxicology studies suggest the safety and benign side effect profile of ALS-886, which could prove beneficial in the use of the compound in the critical care setting and as a potential prophylactic therapy. ALS-886 may also have applicability for other conditions in which free radicals cause tissue damage, such as Acute Respiratory Distress Syndrome (ARDS), ischemic stroke and myocardial infarction. An open IND is in place with the US Food and Drug Administration (FDA) to evaluate ALS-886 in human clinical trials.
About Defence Science and Technology Laboratory (Dstl)
Dstl is an agency of the United Kingdom's Ministry of Defence ("MoD") and exists to supply scientific and technical research and advice to the MoD and other UK government departments. Dstl is the center of scientific excellence for the UK Ministry of Defence, housing one of the largest groups of scientists and engineers in public service in the country. Its broad range of activities includes the provision of biological and chemical defense research supporting the strategic and political aims of MoD.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.
CONTACT: Joe Camp of Advanced Life Sciences Holdings, Inc.,+1-630-754-4352, ; or Media, Melanie Nimrodi,+1-312-546-3508, , or Investors, Kathy Price,+1-213-486-6547, , both of Financial Relations Board, forAdvanced Life Sciences Holdings, Inc. email@example.com firstname.lastname@example.org email@example.com
Web site: http://www.advancedlifesciences.com//
Ticker Symbol: (NASDAQ-NMS:ADLS)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: July 2008